$Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis$

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis

<b>Background/Objectives:</b> Classic Hodgkin lymphoma (cHL) is a predominantly curable B-cell malignancy. However, primary refractory and relapsed (R/R) cHL remain therapeutic challenges, especially in regions with high tuberculosis (TB) prevalence, where clinical and radiologic feature...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mohamed Nazem Alibrahim, Hussein Hammam, Antonino Carbone, Noor Alsaleh, Annunziata Gloghini
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Hemato
Subjects:	relapsed/refractory cHL Hodgkin disease tuberculosis immunotherapy stem cell transplantation
Online Access:	https://www.mdpi.com/2673-6357/6/2/12
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience
by: Vishal Kulkarni, et al.
Published: (2020-01-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment
by: Vanessa Cristaldi, et al.
Published: (2025-03-01)

Tumor‐associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma
by: Maja Dam Andersen, et al.
Published: (2025-07-01)

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis
by: Magdalena Witkowska, et al.
Published: (2025-01-01)

Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment
by: Francesca Conti, et al.
Published: (2025-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Shiliang Ge, et al.
Published: (2025-02-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
by: I. A. Kamaeva, et al.
Published: (2021-06-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck
by: Dennis Christoph Harrer, et al.
Published: (2025-03-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Clinicopathological value of tumor-associated macrophages in adult classical Hodgkin lymphoma in Hawler city
by: Tenya Tariq Abdulhameed, et al.
Published: (2025-04-01)

Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study
by: Mai Alalawi, et al.
Published: (2025-05-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults
by: Tomohiro Aoki, et al.
Published: (2025-05-01)

Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?
by: Evgenia Verrou, et al.
Published: (2025-06-01)

Observations on seasonal occurrence in lymphomas with proven or presumed infectious etiology
by: Ioannis Anagnostopoulos, et al.
Published: (2025-07-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma
by: Maja Dam Andersen, et al.
Published: (2025-08-01)

PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
by: EA Demina
Published: (2018-07-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study
by: Alvaro Hernandez-Caballero, et al.
Published: (2025-07-01)

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
by: Ning Lyu, et al.
Published: (2025-01-01)

Immunochemotherapy of refractory classical Hodgkin's lymphoma with high-dose consolidation and autologous hematopoietic stem cell transplantation complicated by a new coronavirus infection
by: L. S. Khayrullina, et al.
Published: (2022-07-01)

Updates in novel immunotherapeutic strategies for relapsed/refractory AML
by: Sawyer Bawek, et al.
Published: (2024-12-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Response Rate After Modified Regime DHAP and Toxicity with Refractory and Relapsed Disease in Lymphoma Patients
by: Reeta Kumari, et al.
Published: (2023-10-01)

Integrative genomic analysis identifies novel causal genes of Hodgkin’s and non-Hodgkin’s lymphoma
by: Patrick Shi, et al.
Published: (2025-07-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)